The complexity of evolving prescription drug requirements has created challenges for manufacturer compliance efforts. Colorado enacted a drug pricing transparency law that requires pharmaceutical manufacturers to disclose in writing the names and wholesale average cost (WAC) of three generic prescription drugs from the same therapeutic class. Conexus recognized an opportunity to improve compliance and greatly reduce risk by automating the process for our client.
A mid-sized, clinical-stage biopharmaceutical company wanted to streamline its regulatory planning and tracking processes. The client needed additional resources to support a project of this size. The project would require a technical subject matter expert who was familiar with GxP and industry standards. Conexus Solutions, Inc. worked with the team to analyze their current situation and better understand their goals for implementing Veeva Vault.
A clinical-stage oncology biotechnology company did not have adequate resources required to execute a strategic communication plan announcing their regulatory approval. Our flexible services created a unique opportunity for the client to leverage marketing automation tools and templates to bolster the impact and effectiveness of their communications.
A global biopharmaceutical company had been using serveral Veeva Vault solutions for their R&D system including eTMF, Submissions, QualityDocs, QMS, and PromoMats. However, the system had not been updated since 2016 and was no longer effective at supporting complex document approval processes. Conexus designed a comprehensive approach that began with an assessment of the organization’s requirements and the potential impact the system update would have on current business processes.